192 related articles for article (PubMed ID: 21997136)
21. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
22. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
[TBL] [Abstract][Full Text] [Related]
24. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis.
Yashiro M; Chung YS; Nishimura S; Inoue T; Sowa M
Br J Cancer; 1995 Nov; 72(5):1200-10. PubMed ID: 7577468
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Liu X; Guo WJ; Zhang XW; Cai X; Tian S; Li J
Cancer Chemother Pharmacol; 2011 Oct; 68(4):871-8. PubMed ID: 21286718
[TBL] [Abstract][Full Text] [Related]
26. Establishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasis.
Fujihara T; Sawada T; Hirakawa K; Chung YS; Yashiro M; Inoue T; Sowa M
Clin Exp Metastasis; 1998 May; 16(4):389-98. PubMed ID: 9626818
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
Shao J; Xu Z; Peng X; Chen M; Zhu Y; Xu L; Zhu H; Yang B; Luo P; He Q
PLoS One; 2016; 11(1):e0146968. PubMed ID: 26752698
[TBL] [Abstract][Full Text] [Related]
28. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Zhu S; Belkhiri A; El-Rifai W
Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
[TBL] [Abstract][Full Text] [Related]
29. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
31. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
32. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Yoon YK; Kim HP; Han SW; Hur HS; Oh DY; Im SA; Bang YJ; Kim TY
Mol Cancer Ther; 2009 Sep; 8(9):2526-36. PubMed ID: 19755509
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.
Lopes F; Smith R; Nash S; Mitchell RT; Spears N
Mol Hum Reprod; 2016 Nov; 22(11):745-755. PubMed ID: 27470502
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
36. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
[TBL] [Abstract][Full Text] [Related]
39. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice.
Yashiro M; Chung YS; Nishimura S; Inoue T; Sowa M
Clin Exp Metastasis; 1996 Jan; 14(1):43-54. PubMed ID: 8521616
[TBL] [Abstract][Full Text] [Related]
40. Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Zhang X; Yashiro M; Qiu H; Nishii T; Matsuzaki T; Hirakawa K
Anticancer Res; 2010 Mar; 30(3):915-21. PubMed ID: 20393015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]